IRT System Configuration Software aids clinical research.
Press Release Summary:
Built on configurable architecture, PULSE v2.0(TM) enables accelerated configuration of fully validated, custom IRT (Integrated Response Technology) systems for clinical trials. Project managers can create and manage client-specific templates, ensuring every study endpoint develops automatically and contains client's preferred configurations. Platform also offers reports and administrative functionality, with focus on control over clinical supplies.
Original Press Release:
endpoint Launches PULSE 2.0 Allowing Clinical Research Teams to Save Additional Time and Money by Rapidly Deploying Studies with Custom Reporting
Clinical Trial Program Managers Produce Custom, Validated Integrated Response Technology Systems Shaving 40 Percent Off Development Time of Clinical Trials
SAN FRANCISCO -- endpoint Clinical (www.endpointclinical.com), a leader in Integrated Response Technology (IRT) development, today announced the release of PULSE 2.0(TM). endpoint PULSE is a proprietary platform that enables the configuration of fully validated, custom IRT systems for clinical trials in a fraction of the time required by traditional development. New in PULSE 2.0 is the ability for project managers to create and manage client-specific templates, ensuring that every study endpoint develops automatically contains the client's preferred configurations. PULSE 2.0 also offers enhanced reports and administrative functionality, with a focus on improved control over clinical supplies.
endpoint's PULSE configurable architecture meets Clinical Program Managers' demands for making mid-study changes quickly and easily. endpoint's PULSE platform combines IRT capabilities with pre-validated modules allowing clinical trials to move ahead at a more rapid rate due to project managers having access to the configurable design elements rather than relying on custom development for each change.
"Since launching PULSE in February, we've been compiling a long list of new features and functionality," said Jonathan Dole, co-founder and CEO, endpoint. "PULSE 2.0 is a blend of features our customers are asking for and new tools that enable us to deliver an even more robust IRT system in the same timeframe to which our customers are becoming accustomed."
About endpoint
endpoint is an innovative company dedicated to the development of the leading technology platforms for the life sciences industry. endpoint's founding team has been developing IRT systems for clinical trials since 1998 and have deployed systems to small, medium and large pharma for domestic and global studies with experience across a broad range of therapeutic areas and global implementations. For more information, visit endpoint at www.endpointclinical.com.
